The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations

Pigment Cell and Melanoma Research

Volumn 29, Issue 5, 2016, Pages 590-597

  Meeth, Katrina ^a   Wang, Jake Xiao ^a   Micevic, Goran ^a   Damsky, William ^a   Bosenberg, Marcus W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer immunology; cell lines; melanoma; mouse models; YUMM

Indexed keywords

ANIMAL CELL; ANIMAL MODEL; BIOLOGY; C57BL 6 MOUSE; CANCER IMMUNOLOGY; CONGENIC STRAIN; DRIVER; GENOTYPE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; MELANOMA CELL LINE; MOUSE; MOUSE MODEL; MUTATION; NONHUMAN; UNIVERSITY;

EID: 84986921907     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12498     Document Type: Article

References (27)

1. Bertrand, F., Rochotte, J., Colacios, C. et al. (2015). Blocking tumor necrosis factor alpha enhances CD8 T-cell-dependent immunity in experimental melanoma. Cancer Res. 75, 2619–2628.
2. + T cells that impact BRAF-mutant murine melanoma. Melanoma Res. 26, 1–11.
3. Cloudman, A.M. (1941). The effect of an extra-chromo-somal influence upon transplanted spontaneous tumors in mice. Science 93, 380–381.
4. Damsky, W.E., Curley, D.P., Santhanakrishnan, M. et al. (2011). β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20, 741–754.
5. Damsky, W., Micevic, G., Meeth, K. et al. (2015). mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 27, 41–56.
6. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky Jr, W.E., You, M.J., Depinho, R.A., Mcmahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544–552.
7. Gubin, M.M., Zhang, X., Schuster, H. et al. (2014). Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581.
8. Harding, H.E., and Passey, R.D. (1930). A transplantable melanoma of the mouse. J. Pathol. Bacteriol. 33, 417–427.
9. Ho, P.-C., Bihuniak, J.D., Macintyre, A.N. et al. (2015). Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217–1228.
10. de Jel, M.M., Engelmann, J.C., Kunz, M., Schiffner, S., Kuphal, S., and Bosserhoff, A.K. (2014). Transcriptome sequencing of melanocytic nevi and melanomas from Grm1 transgenic mice to determine melanoma driver mutations. Pigment Cell Melanoma Res. 27, 678–80.
11. Jenkins, M.H., Steinberg, S.M., Alexander, M.P., Fisher, J.L., Ernstoff, M.S., Turk, M.J., Mullins, D.W., and Brinckerhoff, C.E. (2014). Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res. 27, 495–501.
12. Jenkins, M.H., Croteau, W., Mullins, D.W., and Brinckerhoff, C.E. (2015). The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Matrix Biol. 48, 66–77.
13. Kaur, A., Webster, M.R., Marchbank, K. et al. (2016). sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532, 250–254.
14. Kershaw, M.H., Hsu, C., Mondesire, W. et al. (2001). Immunization against endogenous retroviral tumor-associated antigens. Cancer Res. 61, 7920–7924.
15. Li, M., Huang, X., Zhu, Z., and Gorelik, E. (1999). Sequence and insertion sites of murine melanoma-associated retrovirus. J. Virol. 73, 9178–9186.
16. Liu, M., Sakamaki, T., Casimiro, M.C. et al. (2010). The canonical NF-κB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 70, 10464–10473.
17. Longley, D., and Johnston, P. (2005). Molecular mechanisms of drug resistance. J. Pathol. 205, 275–292.
18. Luo, X., Mitra, D., Sullivan, R.J., et al. (2014). Isolation and molecular characterization of circulating melanoma cells. Cell Reports. 7, 645–653.
19. Nogueira, C., Kim, K.H., Sung, H., Paraiso, K.H., Dannenberg, J.H., Bosenberg, M., Chin, L., and Kim, M. (2010). Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29, 6222–6232.
20. Obenauf, A.C., Zou, Y., Ji, A.L. et al. (2015). Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520, 368–372.
21. Salas Fragomeni, R.A., Chung, H.W., Landesman, Y., Senapedis, W., Saint-Martin, J.R., Tsao, H., Flaherty, K.T., Shacham, S., Kauffman, M., and Cusack, J.C. (2013). CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol. Cancer Ther. 12, 1171–1179.
22. Scortegagna, M., Ruller, C., Feng, Y. et al. (2014). Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene 33, 4330–4339.
23. Scortegagna, M., Lau, E., Zhang, T. et al. (2015). PDK1 and SGK3 contribute to the growth of BRAF-mutant melanomas and are potential therapeutic targets. Cancer Res. 75, 1399–1412.
24. Semenza, G.L. (2013). Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 32, 4057–4063.
25. Takizawa, H., Sato, S., Kitajima, H., Konishi, S., Iwata, K., and Hayashi, Y. (1985). Mouse skin melanoma induced in two stage chemical carcinogenesis with 7,12-dimethylbenz[a]anthracene and croton oil. Carcinogenesis 6, 921–923.
26. Vanbrocklin, M.W., Robinson, J.P., Lastwika, K.J., Khoury, J.D., and Holmen, S.L. (2010). Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice. Pigment Cell Melanoma Res. 23, 531–541.
27. Ward, J.P., Gubin, M.M., and Schreiber, R.D. (2016). The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv. Immunol. 130, 25–74.